| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
The primary targets of 2'-Aminoacetophenone include mitochondrial pathways, where it induces oxidative stress and disrupts mitochondrial function. By inducing oxidative stress, the compound triggers apoptosis signaling. It also targets autophagy pathways, inhibiting LC3BII and p62 protein levels in macrophages. As a respiratory biomarker, it is used to detect P. aeruginosa infections. These targets make it relevant for infectious disease and apoptosis research.
|
|---|---|
| ln Vitro |
In vitro, 2'-Aminoacetophenone induces apoptosis by disrupting mitochondrial activity through oxidative stress induction. It inhibits LC3BII and p62 protein levels in macrophages and regulates autophagy. The compound is studied in vitro to understand its mechanisms of apoptosis induction and autophagy regulation. These in vitro activities support its use in research on apoptosis, autophagy, and infectious disease biomarkers.
|
| ln Vivo |
In vivo, 2'-Aminoacetophenone is an orally active apoptosis inducer. It is used as a breath biomarker for the detection of Pseudomonas aeruginosa infections in the lungs of cystic fibrosis patients. The compound can disrupt mitochondrial function by inducing oxidative stress and apoptosis signaling, leading to dysfunction in mouse skeletal muscle. These in vivo activities support its use in diagnostic and infectious disease research.
|
| Enzyme Assay |
In vitro assays for 2'-Aminoacetophenone include apoptosis induction studies using various cell lines. Cells are treated with compound concentrations ranging from 0.1-1000 μM for 24-72 hours. Apoptosis is evaluated by annexin V/PI staining, caspase activity assays, and mitochondrial membrane potential measurements. Oxidative stress is measured using ROS detection probes. Autophagy markers (LC3BII, p62) are assessed by Western blot. All assays include appropriate controls and reference compounds.
|
| Cell Assay |
In vitro cell-based assays for 2'-Aminoacetophenone are conducted using macrophages, cancer cell lines, or other relevant cell types. Cells are treated with compound concentrations ranging from 0.1-1000 μM for 24-72 hours. Cell viability is assessed using MTT assays. Apoptosis is evaluated by annexin V/PI staining. Mitochondrial function is assessed using JC-1 staining or Seahorse analysis. Autophagy is assessed by measuring LC3BII and p62 levels. Experiments include vehicle controls and positive controls.
|
| Animal Protocol |
In vivo animal studies with 2'-Aminoacetophenone are conducted in models of P. aeruginosa infection and cystic fibrosis. The compound is administered orally at doses ranging from 1-50 mg/kg. Breath analysis is used to detect the compound as a biomarker of infection. Skeletal muscle function may be assessed in models of oxidative stress-induced dysfunction. Each group consists of 6-10 animals with appropriate controls.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
2-Carboxamido-4-methylquinazoline, 2-hydroxymethyl-4-methylquinazoline, and 4-methylquinazoline are produced in Pseudomonas. /Excerpt from Table/ 2-Amino-3-hydroxyacetophenone was isolated from the urine of rats administered 15 mg/kg body weight of 2-aminoacetophenone daily for 4 consecutive days, and from the supernatant of rat liver microsomal culture incubated with 2-aminoacetophenone at 37°C for 2 hours. In cell-free extracts of Bacillus subtilis, 2'-aminoacetophenone is utilized as rapidly as aminoacetone. Pharmacokinetic properties of 2'-Aminoacetophenone include its oral bioavailability. As a small, lipophilic molecule (MW 135.16, C8H9NO), it is expected to have good absorption and tissue distribution. The compound is a bacterial metabolite and is excreted in breath as a biomarker. It likely undergoes hepatic metabolism through oxidation and conjugation, with elimination via renal and respiratory routes. Detailed PK parameters require further investigation. |
| Toxicity/Toxicokinetics |
Toxicological data for 2'-Aminoacetophenone indicate that it is generally well-tolerated at concentrations used for research. The compound is a bacterial metabolite and is used as a breath biomarker. No significant toxicity has been reported at diagnostic concentrations. However, comprehensive toxicological studies have not been conducted. As with all research chemicals, appropriate safety precautions should be taken during handling.
|
| References | |
| Additional Infomation |
2'-Aminoacetophenone is an aromatic ketone, a compound formed by replacing an ortho-hydrogen molecule on the benzene ring of acetophenone with an amino group. It is a bacterial metabolite. It is a substituted aniline and belongs to the acetophenone class of compounds. 2'-Aminoacetophenone has been reported in Streptomyces, Castanopsis cuspidata, and Vitis vinifera, and relevant data are available.
2'-Aminoacetophenone is an orally active apoptosis inducer and respiratory biomarker used to detect Pseudomonas aeruginosa infections in cystic fibrosis patients. It induces apoptosis by disrupting mitochondrial activity through oxidative stress and regulates autophagy. It is a bacterial metabolite used in research on infectious disease diagnostics, apoptosis, and autophagy. Not approved for clinical therapeutic use; intended for research and diagnostic purposes. |
| Molecular Formula |
C₈H₉NO
|
|---|---|
| Molecular Weight |
135.16
|
| Exact Mass |
135.068
|
| CAS # |
551-93-9
|
| Related CAS # |
25384-14-9 (hydrochloride)
|
| PubChem CID |
11086
|
| Appearance |
Light yellow to yellow <20°C powder,>20°C liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
251.8±13.0 °C at 760 mmHg
|
| Melting Point |
20 °C
|
| Flash Point |
106.1±19.8 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.571
|
| LogP |
1.62
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
133
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=CC(=C1C(C)=O)N
|
| InChi Key |
GTDQGKWDWVUKTI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H9NO/c1-6(10)7-4-2-3-5-8(7)9/h2-5H,9H2,1H3
|
| Chemical Name |
1-(2-aminophenyl)ethanone
|
| Synonyms |
2'Aminoacetophenone; 2' Aminoacetophenone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~739.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.3986 mL | 36.9932 mL | 73.9864 mL | |
| 5 mM | 1.4797 mL | 7.3986 mL | 14.7973 mL | |
| 10 mM | 0.7399 mL | 3.6993 mL | 7.3986 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
